Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruggero Lasala

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Journal of Medical Economics|March 20, 2014
Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysisFiorenzo Santoleri, Paola Sorice, Ruggero Lasala, et al.
Recenti Progressi in Medicina|October 30, 2023
[Clinical trials approved by Aifa for Covid-19: report of the main results to fill the unmet medical need.]Corrado Confalonieri, Arianna Orcesi, Ruggero Lasala, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 13, 2021
Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinomaRuggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, et al.
Hospital Pharmacy|June 26, 2024
Adherence, Persistence, Switching and Costs of Injectable and Oral Therapies for Multiple Sclerosis. Real Life Analysis Over 6 Years of TreatmentFiorenzo Santoleri, Ruggero Lasala, Eleononora Berardini, et al.
European Journal of Clinical Pharmacology|March 4, 2020
Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trialsRuggero Lasala, Andrea Logreco, Alessia Romagnoli, et al.
European Journal of Hospital Pharmacy : Science and Practice|January 21, 2022
Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugsRuggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, et al.
Current Medical Research and Opinion|March 18, 2023
Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overviewRuggero Lasala, Andrea Zovi, Valentina Isgrò, et al.
Recenti Progressi in Medicina|November 17, 2024
Felice Musicco, Ruggero Lasala, Fiorenzo Santoleri, et al.
European Journal of Clinical Nutrition|August 10, 2024
Dietary management and access to treatment for patients with glucose deficiency syndrome type 1: an overview review with focus on the European regulatory frameworkAndrea Zovi, Carlo Cifani, Corrado Confalonieri, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 25, 2021
Available information about paediatric use of onco-haematological drugs authorized by EMA since 2016Ruggero Lasala, Fiorenzo Santoleri, Davide Zanon, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Journal of Medical Economics|March 20, 2014
Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysisFiorenzo Santoleri, Paola Sorice, Ruggero Lasala, et al.
Recenti Progressi in Medicina|October 30, 2023
[Clinical trials approved by Aifa for Covid-19: report of the main results to fill the unmet medical need.]Corrado Confalonieri, Arianna Orcesi, Ruggero Lasala, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 13, 2021
Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinomaRuggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, et al.
Hospital Pharmacy|June 26, 2024
Adherence, Persistence, Switching and Costs of Injectable and Oral Therapies for Multiple Sclerosis. Real Life Analysis Over 6 Years of TreatmentFiorenzo Santoleri, Ruggero Lasala, Eleononora Berardini, et al.
European Journal of Clinical Pharmacology|March 4, 2020
Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trialsRuggero Lasala, Andrea Logreco, Alessia Romagnoli, et al.
European Journal of Hospital Pharmacy : Science and Practice|January 21, 2022
Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugsRuggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, et al.
Current Medical Research and Opinion|March 18, 2023
Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overviewRuggero Lasala, Andrea Zovi, Valentina Isgrò, et al.
Recenti Progressi in Medicina|November 17, 2024
Felice Musicco, Ruggero Lasala, Fiorenzo Santoleri, et al.
European Journal of Clinical Nutrition|August 10, 2024
Dietary management and access to treatment for patients with glucose deficiency syndrome type 1: an overview review with focus on the European regulatory frameworkAndrea Zovi, Carlo Cifani, Corrado Confalonieri, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 25, 2021
Available information about paediatric use of onco-haematological drugs authorized by EMA since 2016Ruggero Lasala, Fiorenzo Santoleri, Davide Zanon, et al.
Pageof 4